BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 9405901)

  • 1. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.
    Holleman F; Schmitt H; Rottiers R; Rees A; Symanowski S; Anderson JH
    Diabetes Care; 1997 Dec; 20(12):1827-32. PubMed ID: 9405901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.
    Melki V; Renard E; Lassmann-Vague V; Boivin S; Guerci B; Hanaire-Broutin H; Bringer J; Belicar P; Jeandidier N; Meyer L; Blin P; Augendre-Ferrante B; Tauber JP
    Diabetes Care; 1998 Jun; 21(6):977-82. PubMed ID: 9614617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.
    Heller SR; Amiel SA; Mansell P
    Diabetes Care; 1999 Oct; 22(10):1607-11. PubMed ID: 10526722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study.
    Johansson UB; Adamson UC; Lins PE; Wredling RA
    Diabetes Metab; 2000 May; 26(3):192-6. PubMed ID: 10880892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin lispro in CSII: results of a double-blind crossover study.
    Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
    Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.
    Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J
    Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Keohane P; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
    Arch Intern Med; 1997 Jun; 157(11):1249-55. PubMed ID: 9183237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Koivisto VA; Pfützner A; Trautmann ME; Vignati L; DiMarchi R
    Diabetes; 1997 Feb; 46(2):265-70. PubMed ID: 9000704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
    Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
    Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
    Vignati L; Anderson JH; Iversen PW
    Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM.
    Burge MR; Castillo KR; Schade DS
    Diabetes Care; 1997 Feb; 20(2):152-5. PubMed ID: 9118763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
    Lalli C; Ciofetta M; Del Sindaco P; Torlone E; Pampanelli S; Compagnucci P; Cartechini MG; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P; Trautmann M; Arora V; Sun B; Anderson JH
    Clin Ther; 1999 Mar; 21(3):523-34. PubMed ID: 10321421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin.
    Tsui EY; Chiasson JL; Tildesley H; Barnie A; Simkins S; Strack T; Zinman B
    Diabetes Care; 1998 Jan; 21(1):93-6. PubMed ID: 9538976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus.
    Ford-Adams ME; Murphy NP; Moore EJ; Edge JA; Ong KL; Watts AP; Acerini CL; Dunger DB
    Diabet Med; 2003 Aug; 20(8):656-60. PubMed ID: 12873294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.
    Holcombe JH; Zalani S; Arora VK; Mast CJ;
    Clin Ther; 2002 Apr; 24(4):629-38. PubMed ID: 12017407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.
    Ebeling P; Jansson PA; Smith U; Lalli C; Bolli GB; Koivisto VA
    Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
    Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
    Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.